Bentley Pharmaceuticals Appoints Dr. Fred Feldman Vice President of Research and Development.

EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that Fred Feldman, Ph.D., joins the Exeter-based research unit on October 31, 2005. Dr. Feldman is an experienced life sciences researcher with more than 25 years of product development expertise.

Dr. Feldman received his B.S. degree in Biochemistry from the University of Chicago and Ph.D. in Biochemistry from Purdue University. While Vice President of Pre-Clinical R&D at Armour Pharmaceutical Company and later at Rhone Poulenc Rorer after its acquisition of Armour, he developed new products and spearheaded registration activities in the U.S. and international markets. He was a leader in the development of lifesaving drugs for chronic diseases and replacement therapies that were registered and commercialized worldwide.

Dr. Feldman went on to become Senior Vice President, Worldwide Head of Pre-Clinical R&D and Head of Biotechnology for Centeon, LLC and Aventis Behring, both Aventis Pharma subsidiaries, setting strategic scientific direction in such disciplines as gene therapy and therapeutic protein delivery. He has also been a high-level advisor to various venture capital investment organizations involved in a broad range of biotechnology and pharmaceutical applications.

James R. Murphy, Bentley's Chairman and CEO, commented, "We are excited to have Fred join our scientific team and bring added strength to our existing group of accomplished scientists. Fred's experience in developing complex molecules and peptides will be a valuable asset to our company. He not only has relevant experience in the development of products for long-term critical care, but is intimately familiar with the rapidly growing advances in nanoparticle research that will be pivotal in applying Bentley's advanced drug-delivery technologies for diabetes and other serious diseases."

John A. Sedor, President of Bentley, said "I have known and worked with Fred for over 20 years. He is an outstanding scientist with a strong track record in developing and bringing products to market including biologics and monoclonal antibodies. Fred will bring an added dimension to Bentley and our technologies with his vast knowledge of proteins and peptides."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding Bentley's prospects for its research and development programs and personnel. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the timing and results of clinical trials, efficacy and safety of our products, the timing and nature of regulatory approvals, development and commercialization of our products and formulations, competition from other manufacturers of generic and proprietary pharmaceuticals, intellectual property litigation, Bentley's relationships with its strategic partners, the unpredictability of patent protection, technological changes, the effects of economic conditions, risks associated with international operations, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.